GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (LTS:0UNL) » Definitions » Purchase Of Business

Nektar Therapeutics (LTS:0UNL) Purchase Of Business : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Nektar Therapeutics Purchase Of Business?

Nektar Therapeutics's purchase of business for the three months ended in Dec. 2024 was $0.00 Mil. It means Nektar Therapeutics spent $0.00 Mil on purchasing business. Nektar Therapeutics's purchase of business for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Compared with last quarter ($0.00 Mil in Sep. 2024 ), Nektar Therapeutics spent the same money on purchasing business in Dec. 2024 ($0.00 Mil).

Nektar Therapeutics Purchase Of Business Historical Data

The historical data trend for Nektar Therapeutics's Purchase Of Business can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nektar Therapeutics Purchase Of Business Chart

Nektar Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Purchase Of Business
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nektar Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Purchase Of Business Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Nektar Therapeutics Purchase Of Business Calculation

The amount used to purchase business.

Purchase Of Business for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nektar Therapeutics Purchase Of Business Related Terms

Thank you for viewing the detailed overview of Nektar Therapeutics's Purchase Of Business provided by GuruFocus.com. Please click on the following links to see related term pages.

Nektar Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nektar Therapeutics (LTS:0UNL) » Definitions » Purchase Of Business
Comparable Companies
LXEO SCPH GLSI NKTX TLSA ADCT ZNTL TNXP ALEC PRQR VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
NKTR:USA NKTR:Mexico ITH:Germany ITH:Germany
Address
455 Mission Bay Boulevard South, San Francisco, CA, USA, 94158
Website
https://www.nektar.com
Nektar Therapeutics is a clinical-stage, research-based drug discovery biopharmaceutical company focused on discovering and developing medicines in the field of immunotherapy. The company is focused on discovering and developing medicines in the field of immunotherapy. Its pipeline products are REZPEG (NKTR-358), REZPEG (NKTR-358), REZPEG (NKTR-358), NKTR-422, NKTR-0165, NKTR-255, and Others.

Nektar Therapeutics Headlines

No Headlines